Advertisement: HCR Hewitsons mid banner
Advertisement: Simpsons Creative mid banner
Advertisement: partnersand mid banner
Cambridgeand mid banner advertisement
Advertisement mid banner S-Tech 1
Advertisement: Bar Ellison mid banner property
Advertisement: SATAVIA mid banner
Advertisement: Cambridge Network mid banner
ARM Innovation Hub
Advertisement: Birketts mid banner
Mid banner advertisement: BDO
Advertisement: CJBS mid banner
Barr Ellison Solicitors – commercial property
Advertisement: Mogrify mid banner
Advertisement: Kao Data Centre mid banner
Advertisement: RSM mid banner
28 June, 2022 - 13:07 By Tony Quested

Dunad unveils Pearl with the world its oyster

Dunad Therapeutics has appointed pharmaceutical industry ‘evergreen’ Dr Pearl Huang as CEO.

She brings more than 30 years of biopharma experience, most recently as chief executive and president of pioneering start-up Cygnal Therapeutics – spun out of Flagship Pioneering where she was a venture partner.

Her biotech and pharma industry experience spans leadership positions at major pharma companies such as Roche, GSK and Merck, to name a few. 

Dunad is focused on developing small molecule covalent therapies based on novel insights from chemistry and protein degradation. 

While Dunad is headquartered in Cambridge UK, Dr. Huang will be based out of the Cambridge Massachusetts office in the US. The company also has operations in Toronto in Canada.

Initially, Dunad is focused on oncology and inflammation with plans to expand into other disease areas. Late last year, Dunad made headlines with its strategic collaboration and licence agreement with Novartis, leveraging its platform to develop novel oral targeted protein degrader therapies. 

The appointment comes as Dunad establishes its US operations, continues to expand its platform based on novel insights into covalent chemistry and build sits internal drug discovery programs.

Dr Huang said: “I feel privileged and excited to join the Dunad team, which is harnessing fundamentally new chemistry to create precision covalent small molecule therapies and has developed a chemo-proteomics platform to go after disease-driving protein targets.

“While the company’s platform unlocks the opportunity to immediately generate highly differentiated next-generation protein degrader therapies, the true potential of the platform goes far beyond this therapeutic modality. 

“Dunad’s foundational science has truly disrupted the landscape for small molecule drug discovery and I am thrilled for the opportunity to deliver the next generation of covalent, tunable and highly specific small molecule treatments for a broad range of diseases.”

Patrick Gunning, co-founder and chief scientific officer at Dunad, explained the global significance of Dr Huang’s appointment.

He said: “Pearl is a highly respected leader in the industry with experience working in both biotech and pharma and we are thrilled to have her joining Dunad at this critical time of growth for the company.

“We are building our North American presence while continuing to expand our platform and optimise our internal drug discovery programs. Pearl’s leadership and experience will ensure success for Dunad during this transformational time as we build on our strong scientific foundation and seek to realise the full value of our platform.”

Founded in 2020, Dunad is backed by founding investor Epidarex Capital as well as BioGeneration Ventures (BGV) and Novartis. 

Newsletter Subscription

Stay informed of the latest news and features